$MAIA
MAIA Biotechnology, Inc.

2024 Q1 Form 10-K Financial Statement

#000095017024034764 Filed on March 21, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.628M $2.660M $9.070M
YoY Change -18.11% 47.67% 25.23%
% of Gross Profit
Research & Development $2.321M $3.717M $11.11M
YoY Change 5.68% 55.32% 24.39%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.949M $6.378M $20.18M
YoY Change -5.63% 52.03% 24.77%
Operating Profit -$3.949M -$20.18M
YoY Change -5.63% 24.77%
Interest Expense $44.12K $30.72K $6.863K
YoY Change 757.2% -778.15% -1.49%
% of Operating Profit
Other Income/Expense, Net -$4.163M $90.46K $381.9K
YoY Change -5866.31% 68.14% -7.32%
Pretax Income -$8.067M -$6.257M -$19.80M
YoY Change 95.96% 50.92% 25.32%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$8.067M -$6.257M -$19.77M
YoY Change 95.96% 50.92% 25.39%
Net Earnings / Revenue
Basic Earnings Per Share -$0.46 -$1.49
Diluted Earnings Per Share -$0.46 -$0.40 -$1.49
COMMON SHARES
Basic Shares Outstanding 20.00M 14.21M 13.26M
Diluted Shares Outstanding 17.60M 13.26M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.271M $7.151M $7.151M
YoY Change 9.03% -34.7% -34.7%
Cash & Equivalents $0.00 $0.00
Short-Term Investments
Other Short-Term Assets $272.6K $268.7K $268.7K
YoY Change -31.66% -51.53% -51.53%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $8.700M $7.564M $7.564M
YoY Change 4.4% -35.94% -35.94%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.800K $2.800K $2.800K
YoY Change 0.0% 0.0% -98.69%
Total Long-Term Assets $16.04K $2.800K $2.800K
YoY Change -97.83% -98.69% -98.69%
TOTAL ASSETS
Total Short-Term Assets $8.700M $7.564M $7.564M
Total Long-Term Assets $16.04K $2.800K $2.800K
Total Assets $8.716M $7.567M $7.567M
YoY Change -3.95% -37.06% -37.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.873M $1.639M $1.639M
YoY Change 66.09% 40.59% 40.59%
Accrued Expenses $3.035M $3.299M $3.299M
YoY Change 15.01% 56.82% 56.82%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.908M $4.937M $4.937M
YoY Change 30.3% 51.03% 51.03%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $9.573M $2.152M $2.152M
YoY Change 4166.13% 777.23% 777.23%
Total Long-Term Liabilities $9.573M $2.152M $2.152M
YoY Change 4166.13% 777.23% 777.23%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.908M $4.937M $4.937M
Total Long-Term Liabilities $9.573M $2.152M $2.152M
Total Liabilities $14.48M $7.089M $7.089M
YoY Change 262.85% 101.73% 101.73%
SHAREHOLDERS EQUITY
Retained Earnings -$72.05M -$63.98M
YoY Change 49.09% 44.73%
Common Stock $2.059K $1.699K
YoY Change 87.18% 55.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.765M $477.5K $477.5K
YoY Change
Total Liabilities & Shareholders Equity $8.716M $7.567M $7.567M
YoY Change -3.95% -37.06% -37.06%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$8.067M -$6.257M -$19.77M
YoY Change 95.96% 50.92% 25.39%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$3.587M -$3.992M -$13.07M
YoY Change 6.73% 59.1% 12.14%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.717M 5.025M 9.271M
YoY Change -893.56% -22.98%
NET CHANGE
Cash From Operating Activities -3.587M -3.992M -13.07M
Cash From Investing Activities
Cash From Financing Activities 4.717M 5.025M 9.271M
Net Change In Cash 1.121M 1.033M -3.800M
YoY Change -133.31% -132.87% -1109.0%
FREE CASH FLOW
Cash From Operating Activities -$3.587M -$3.992M -$13.07M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001878313
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201602Member
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-41455
CY2023 dei Entity Registrant Name
EntityRegistrantName
MAIA BIOTECHNOLOGY, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1495913
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
444 West Lake Street
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1700
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Chicago
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
IL
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
06060
CY2023 dei City Area Code
CityAreaCode
312
CY2023 dei Local Phone Number
LocalPhoneNumber
416-8592
CY2023 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2023 dei Trading Symbol
TradingSymbol
MAIA
CY2023 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16986254
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16986254
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10955904
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
22484200
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20002826
CY2023 dei Auditor Firm
AuditorFirmId
248
CY2023 dei Auditor Name
AuditorName
GRANT THORNTON LLP
CY2023 dei Auditor Location
AuditorLocation
Charlotte, North Carolina
CY2023Q4 us-gaap Cash
Cash
7150695
CY2022Q4 us-gaap Cash
Cash
10950927
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
268677
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
554321
CY2023Q4 maia Research And Development Incentives Receivable
ResearchAndDevelopmentIncentivesReceivable
144680
CY2022Q4 maia Research And Development Incentives Receivable
ResearchAndDevelopmentIncentivesReceivable
302789
CY2023Q4 us-gaap Assets Current
AssetsCurrent
7564052
CY2022Q4 us-gaap Assets Current
AssetsCurrent
11808037
CY2022Q4 us-gaap Deferred Costs
DeferredCosts
211203
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2800
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2800
CY2023Q4 us-gaap Assets
Assets
7566852
CY2022Q4 us-gaap Assets
Assets
12022040
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1638546
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1165505
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3298607
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2103401
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4937153
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3268906
CY2023Q4 maia Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
2152188
CY2022Q4 maia Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
245341
CY2023Q4 us-gaap Liabilities
Liabilities
7089341
CY2022Q4 us-gaap Liabilities
Liabilities
3514247
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10955904
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1699
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1096
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
64472249
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
52729942
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-63980177
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44207272
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16260
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-15973
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
477511
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8507793
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7566852
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12022040
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11112257
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8933314
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9070124
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6143527
CY2022 maia Ratchet Share Expense
RatchetShareExpense
1099360
CY2023 us-gaap Operating Expenses
OperatingExpenses
20182381
CY2022 us-gaap Operating Expenses
OperatingExpenses
16176201
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-20182381
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-16176201
CY2023 us-gaap Interest Expense
InterestExpense
6863
CY2022 us-gaap Interest Expense
InterestExpense
6967
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
34490
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
1870
CY2023 maia Australian Research And Development Incentives
AustralianResearchAndDevelopmentIncentives
176719
CY2022 maia Australian Research And Development Incentives
AustralianResearchAndDevelopmentIncentives
313625
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-205130
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-98394
CY2023 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
409476
CY2022 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
406922
CY2023 us-gaap Profit Loss
ProfitLoss
-19772905
CY2022 us-gaap Profit Loss
ProfitLoss
-15769279
CY2022 maia Deemed Dividend On Warrant Modification
DeemedDividendOnWarrantModification
-450578
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19772905
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16219857
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.49
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.49
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.75
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.75
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13261572
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13261572
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9276761
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9276761
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19772905
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16219857
CY2023 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-287
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-15973
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19773192
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16235830
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8507793
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1433
CY2023 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
731661
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3089304
CY2023 maia Stock Issued During Period Value Warrants To Underwiter
StockIssuedDuringPeriodValueWarrantsToUnderwiter
241109
CY2023 maia Issuance Of Stock Options To Satisfy Accrued Bonus
IssuanceOfStockOptionsToSatisfyAccruedBonus
974224
CY2023 maia Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
-287
CY2023 us-gaap Profit Loss
ProfitLoss
-19772905
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
477511
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9181203
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
84000
CY2022 maia Issuance Of Common Shares Upon Exercise Of Warrants
IssuanceOfCommonSharesUponExerciseOfWarrants
385400
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2319427
CY2022 maia Issuance Of Common Shares In Connection With Equity Financing
IssuanceOfCommonSharesInConnectionWithEquityFinancing
2473560
CY2022 maia Modification Of Warrant In Equity
ModificationOfWarrantInEquity
450578
CY2022 maia Adjustments Additional Paid In Capital Deemed Dividend Modification Of Warrant
AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant
-450578
CY2022 maia Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
-15973
CY2022 us-gaap Profit Loss
ProfitLoss
-15769279
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8507793
CY2023 us-gaap Profit Loss
ProfitLoss
-19772905
CY2022 us-gaap Profit Loss
ProfitLoss
-15769279
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
3089304
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
2319427
CY2022 maia Issuance Of Ratchet Shares
IssuanceOfRatchetShares
1099360
CY2023 maia Consulting Expense For Restricted Shares Issued
ConsultingExpenseForRestrictedSharesIssued
731661
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-205130
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-98394
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-285831
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
505233
CY2023 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-158405
CY2022 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
269395
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-322
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
471897
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
211346
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2169921
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
915742
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13071016
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12096104
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2473560
CY2022 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
440379
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1432
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
84000
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
385400
CY2022 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
11500000
CY2022 maia Payment Of Initial Public Offering Transaction Costs
PaymentOfInitialPublicOfferingTransactionCosts
-2406170
CY2023 maia Proceeds From Sale Of Common Stock In Follow On Offering
ProceedsFromSaleOfCommonStockInFollowOnOffering
5749875
CY2023 maia Proceeds From Direct Offering
ProceedsFromDirectOffering
4000001
CY2023 maia Proceeds From At The Market Offering
ProceedsFromAtTheMarketOffering
1667084
CY2023 maia Payment Of Offering Transactions Costs
PaymentOfOfferingTransactionsCosts
2147491
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9270901
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12477169
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-117
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-4430
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3800232
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
376635
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-63980177
CY2023Q4 us-gaap Cash
Cash
7150695
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10950927
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10574292
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7150695
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10950927
CY2022 maia Previously Paid Issuance Costs In Connection With The Initial Public Offering
PreviouslyPaidIssuanceCostsInConnectionWithTheInitialPublicOffering
651582
CY2022 maia Warrants Issued To Underwriters In Connection With The Initial Public Offering
WarrantsIssuedToUnderwritersInConnectionWithTheInitialPublicOffering
343735
CY2023 maia Options Issued For Accrued Bonus
OptionsIssuedForAccruedBonus
974224
CY2023 maia Warrants Issued To Underwriters In Connection With The Follow On Offering
WarrantsIssuedToUnderwritersInConnectionWithTheFollowOnOffering
241109
CY2023 maia Warrants Issued In Connection With The At The Market Offering
WarrantsIssuedInConnectionWithTheAtTheMarketOffering
84251
CY2023 maia Warrants Issued In Connection With The Direct Offering
WarrantsIssuedInConnectionWithTheDirectOffering
1903915
CY2023 maia Warrants Issued To Underwriters In Connection With The Direct Offering
WarrantsIssuedToUnderwritersInConnectionWithTheDirectOffering
123811
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-08-03
CY2023 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
minority stockholder of THIO received one share of MAIA common stock for each share of THIO common stock owned prior to the merger.
CY2023 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1
CY2023Q4 maia Working Capital
WorkingCapital
2626899
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-63980177
CY2023Q4 us-gaap Cash
Cash
7150695
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4937153
CY2023 us-gaap Revenues
Revenues
0
CY2023Q1 maia Issuance Of Stock Options To Settle Accrued Bonus Balance
IssuanceOfStockOptionsToSettleAccruedBonusBalance
974046
CY2023Q1 maia Fair Value Of Stock Options Issued To Settle Accrued Bonus Balance
FairValueOfStockOptionsIssuedToSettleAccruedBonusBalance
977123
CY2023Q4 maia Accrued Severance Current
AccruedSeveranceCurrent
824435
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s audited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to the valuation of stock options and warrants, and prepaids or accruals for outsourced research and development activities. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</span></p>
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0
CY2023Q4 us-gaap Derivative Assets
DerivativeAssets
0
CY2022Q4 us-gaap Derivative Assets
DerivativeAssets
0
CY2022Q4 us-gaap Deferred Costs
DeferredCosts
211203
CY2023Q4 us-gaap Deferred Costs
DeferredCosts
0
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
786999
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1094582
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
77942
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
332589
CY2023Q4 maia Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
998838
CY2022Q4 maia Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
516961
CY2023Q4 maia Accrued Severance Current
AccruedSeveranceCurrent
824435
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
610393
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
159269
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3298607
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2103401
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
786999
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1094582
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2152188
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
245341
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2373561
CY2022Q1 maia Transaction Costs
TransactionCosts
0
CY2022Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
99999
CY2022Q2 maia Transaction Costs
TransactionCosts
0
CY2022Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
9
CY2022Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9100000
CY2022Q2 maia Warrants Exercised Shares
WarrantsExercisedShares
394501
CY2022Q2 maia Cashless Exercise At Fair Market Value Per Share
CashlessExerciseAtFairMarketValuePerShare
9
CY2022Q2 maia Issuance Of Common Shares Upon Cashless Exercise Of Warrants Shares
IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares
315601
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.25
CY2022Q3 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2023-01-23
CY2022Q3 maia Class Of Warrant Or Right Date From Which Warrants Or Rights Expire
ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire
2027-07-27
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
796985
CY2022Q4 maia Class Of Warrants Weighted Average Exercise Price
ClassOfWarrantsWeightedAverageExercisePrice
6.04
CY2022 maia Class Of Warrants Weighted Average Remaining Contractual Term
ClassOfWarrantsWeightedAverageRemainingContractualTerm
P5Y1M28D
CY2023 maia Class Of Warrants Issued
ClassOfWarrantsIssued
2853293
CY2023 maia Class Of Warrants Weighted Average Exercise Price Issued
ClassOfWarrantsWeightedAverageExercisePriceIssued
1.93
CY2023 maia Class Of Warrants Exercised
ClassOfWarrantsExercised
0
CY2023 maia Class Of Warrants Weighted Average Exercise Price Exercised
ClassOfWarrantsWeightedAverageExercisePriceExercised
0
CY2023 maia Class Of Warrants Expired
ClassOfWarrantsExpired
0
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3089303
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2319427
CY2023 maia Class Of Warrants Weighted Average Exercise Price Expired
ClassOfWarrantsWeightedAverageExercisePriceExpired
0
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3650278
CY2023Q4 maia Class Of Warrants Weighted Average Exercise Price
ClassOfWarrantsWeightedAverageExercisePrice
2.82
CY2023 maia Class Of Warrants Weighted Average Remaining Contractual Term
ClassOfWarrantsWeightedAverageRemainingContractualTerm
P5Y
CY2023 maia Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Percentage Of Shares Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted
0.10
CY2023 maia Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price Percentage
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage
1.10
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6545628
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.55
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M2D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1607027
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.55
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
750
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.91
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
401753
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.53
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7750152
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.53
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M14D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
16329
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7071064
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.38
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y1M13D
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
16229
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
5226712
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3294955
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1378351
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1183941
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
3183980
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1499300
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
584001
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
244848
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
6724
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
10373044
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
6229768
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
10373044
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
6229768
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4100000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1200000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19800000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-19600000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-200000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15800000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-15300000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-500000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.011
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.077
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.022
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.012
CY2023 maia Effective Income Tax Rate Reconciliation Loss On Extinguishment Of Debt
EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt
0
CY2022 maia Effective Income Tax Rate Reconciliation Loss On Extinguishment Of Debt
EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebt
-0.015
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.01
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.03
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.209
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.076
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0

Files In Submission

Name View Source Status
0000950170-24-034764-index-headers.html Edgar Link pending
0000950170-24-034764-index.html Edgar Link pending
0000950170-24-034764.txt Edgar Link pending
0000950170-24-034764-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img119538879_0.jpg Edgar Link pending
img119538879_1.jpg Edgar Link pending
img119538879_10.jpg Edgar Link pending
img119538879_11.jpg Edgar Link pending
img119538879_12.jpg Edgar Link pending
img119538879_13.jpg Edgar Link pending
img119538879_2.jpg Edgar Link pending
img119538879_3.jpg Edgar Link pending
img119538879_4.jpg Edgar Link pending
img119538879_5.jpg Edgar Link pending
img119538879_6.jpg Edgar Link pending
img119538879_7.jpg Edgar Link pending
img119538879_8.jpg Edgar Link pending
img119538879_9.jpg Edgar Link pending
maia-20231231.htm Edgar Link pending
maia-20231231.xsd Edgar Link pending
maia-ex21_1.htm Edgar Link pending
maia-ex23_1.htm Edgar Link pending
maia-ex31_1.htm Edgar Link pending
maia-ex31_2.htm Edgar Link pending
maia-ex32_1.htm Edgar Link pending
maia-ex32_2.htm Edgar Link pending
maia-ex4_1.htm Edgar Link pending
maia-ex97_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
maia-20231231_htm.xml Edgar Link completed
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending